• 1
    Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 2005; 23: 1325.
  • 2
    Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85151.
  • 3
    Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 21723.
  • 4
    Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 2006; 1084: 129.
  • 5
    World Health Organization (WHO). The World Health Report 2002: Reducing Risks, Promoting Healthy Life. WHO, (accessed July 2007).
  • 6
    Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143421.
  • 7
    Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 107.
  • 8
    Walley T, Duggan AK, Haycox AR, Niziol CJ. Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. J R Soc Med 2003; 96: 52531.
  • 9
    Saaddine JB, Cadwell B, Gregg EW et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006; 144: 46574.
  • 10
    Stratton IM, Adler AI, Nell HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 40512.
  • 11
    Halpern MT, Khan ZM, Schmier JK et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47: 103948.
  • 12
    Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics 2001; 19: 33747.
  • 13
    Hughes DA, Bagust A, Haycox A et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 60115.
  • 14
    Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
  • 15
    Bramley TJ, Gerbino PP, Nightengale BS et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 23945.
  • 16
    Skaer TL, Sclar DA, Robison LM. Noncompliance with antihypertensive therapy. Economic consequences. Pharmacoeconomics 1996; 9: 14.
  • 17
    Ho PM, Rumsfeld JS, Masoudi FA et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 183641.
  • 18
    World Health Organization (WHO). Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO, 2003.
  • 19
    Medication Compliance and Persistence Special Interest Group (MCP). Accomplishments. International Society for Pharmacoeconomics & Outcomes Research (ISPOR), (accessed July 2007).
  • 20
    Theibaud P, Patel B, Nichol M, Berenbeim D. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005; 11: 6704.
  • 21
    Clark WF, Churchill DN, Forwell L et al. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000; 162: 1958. Erratum in: CMAJ 2000; 162: 973. Comment in: CMAJ 2000; 162: 1553–4.
  • 22
    Balkrishnan R, Rajagopalan R, Camacho FT et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003; 25: 295871.
  • 23
    Balkrishnan R, Rajagopalan R, Shenolikar RA et al. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. Curr Med Res Opin 2004; 20: 163340.
  • 24
    Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004; 10 (2 Pt 2): 14451.
  • 25
    Herman WH, Hoerger TJ, Brandle M et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 32332.
  • 26
    Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005; 11: S1706.
  • 27
    Shenolikar RA, Balkrishnan R, Camacho FT et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006; 28: 1199207.
  • 28
    Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999; 15: 21728.
  • 29
    Tsuyuki RT, Fradette M, Johnson JA et al. A multicenter disease management program for hospitalized patients with heart failure. J Card Fail 2004; 10: 47380.
  • 30
    Cheng CWR, Chan JCN, Tomlinson B et al. Factors associated with healthcare utilization costs for statin therapy – a pilot study in Hong Kong. Int J Clin Pharmacol Ther 2006; 44: 4848.
  • 31
    Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for healthcare costs. Clin Ther 1997; 19: 144657; discussion 1424–5.
  • 32
    Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 5337.
  • 33
    Degli Esposti E, Sturani A, Degli Esposti L et al. Pharmacoutilization of antihypertensive drugs: a model of analysis. Int J Clin Pharmacol Ther 2001; 39: 2518.
  • 34
    Degli Esposti E, Sturani A, Di Martino M et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 43944.
  • 35
    Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001; 19: 14955.
  • 36
    Urquhart J. Some economic consequences of noncompliance. Curr Hypertens Rep 2001; 3: 47380.
  • 37
    Côte I, Gregoire JP, Moisan J et al. A pharmacy-based health promotion program in hypertension: cost-benefit analysis. Pharmacoeconomics 2003; 21: 41528.
  • 38
    Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003; 9: 32432.
  • 39
    Esposti LD, Di Martino M, Saragoni S et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich) 2004; 6: 7684.
  • 40
    Rosen AB, Hamel MB, Weinstein MC et al. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005; 143: 8999.
  • 41
    Rizzo JA, Abbott TA, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996; 5: 24965.
  • 42
    Plans-Rubió P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain. Pharmacoeconomics 1998; 13 (5 Pt 2): 62343.
  • 43
    Sokol MC, McGuigan KA, Verbrugge RR et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 52130.
  • 44
    GoldMR, SiegelJE, RussellLB, WeinsteinMC, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 45
    Van Wijk BL, Klungel OH, Heerdink ER, De Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 21017.
  • 46
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group. The effect of angiotensin-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 145662.
  • 47
    Huse DM, Russell MW, Miller JD et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82: 135763.
  • 48
    Ramsey SD, Neil N, Sullivan SD et al. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract 1999; 12: 10514.
  • 49
    Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999; 131: 6607.
  • 50
    Plauschinat CA, Nguyen AB, Frech FH et al. Patient compliance and persistence with combination valsartan/hydrochlorothiazide therapy versus hydrochlorothiazide therapy. New York: Poster presented at American Society of Hypertension (ASH) meeting, 2004.
  • 51
    Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (9 Suppl.): S26.
  • 52
    Sturkenboom MCJM, Picelli G, Dieleman JP et al. Patient adherence and persistence with antihypertensive therapy: one-versus two-pill combinations. J Hypertens 2005; 23 (Suppl. 2): S236.
  • 53
    DiMatteo MR, Giordani PJ, Lepper HS et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794811.